E Morando, L Losso, M Carollo, I Costantini… - Heliyon, 2024 - cell.com
This case report examines the combined use of fibrinogen concentrate, four-factor prothrombin complex concentrate (PCC), and idarucizumab, a specific antidote for …
Background and aim: Many patients are treated with several drugs concomitantly, implying a risk of drug interactions. The clinical consequences of drug interactions depend not only on …